Recruiting PHASE1 INTERVENTIONAL 9-arm NCT07011511

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

A First-in-Human, Single-Centre, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Intramuscular Injection(s) of Long-Acting Injectable Formulations of MMV055 Alone (Part A) and in Combination With MMV371 (Part B) in Healthy Participants

Sponsor: Medicines for Malaria Venture

Conditions Malaria, Falciparum

Interventions MMV055 Dose 1 MMV055 Dose 2 MMV055 Dose 3 MMV055 Dose 4 MMV055 Dose 5 MMV055 Dose 6 MMV055/MM371 Combo 2 MMV055/MMV371 Combo 1 MMV055/MMV371 Combo 3 Matching placebo Part A Matching placebo Part B

Updated 2 times since 2025 Last updated: Jul 2, 2025 Started: Jun 30, 2025 Primary completion: Dec 2, 2027 Completion: Dec 2, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Malaria, Falciparum, this trial is actively recruiting participants. The trial is conducted by Medicines for Malaria Venture and has accumulated 2 data snapshots since 2025. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

2 versions recorded

Aug 2025 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jun 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medicines for Malaria Venture
Quotient Sciences
The Doctors Laboratory Ltd

Data source: Medicines for Malaria Venture

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom